JGC
KPTI icon

J. Goldman & Co’s Karyopharm Therapeutics KPTI Stock Holding History

J. Goldman & Co’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-8,000
Closed -$161K – 412
2023
Q3 		$161K Sell
8,000
-27,983
-78% -$628K 0.01% 322
2023
Q2 		$966K Buy
+35,983
New +$1.55M 0.04% 254
2022
Q1 		– Sell
-18,283
Closed -$1.76M – 408
2021
Q4 		$1.76M Buy
18,283
+14,435
+375% +$1.44M 0.1% 214
2021
Q3 		$336K Sell
3,848
-63,149
-94% -$6.56M 0.02% 298
2021
Q2 		$10.4M Sell
66,997
-21,743
-25% -$3.16M 0.4% 64
2021
Q1 		$14M Buy
88,740
+71,291
+409% +$15M 0.45% 51
2020
Q4 		$4.05M Buy
17,449
+5,322
+44% +$1.23M 0.21% 132
2020
Q3 		$2.66M Buy
12,127
+5,377
+80% +$1.32M 0.18% 151
2020
Q2 		$1.92M Buy
6,750
+4,864
+258% +$1.44M 0.12% 163
2020
Q1 		$543K Sell
1,886
-350
-16% -$96.5K 0.07% 168
2019
Q4 		$643K Sell
2,236
-18,403
-89% -$3.99M 0.05% 207
2019
Q3 		$2.98M Buy
+20,639
New +$2.8M 0.22% 123

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

J. Goldman & Co's KPTI Position: Q4 2023 in Review

J. Goldman & Co sold out of Karyopharm Therapeutics (KPTI) in Q4 2023, closing a stake of 8,000 shares — an estimated $161K sold.

J. Goldman & Co first reported a position in KPTI in Q3 2019 and held it in 12 quarters. The position peaked at $14M in Q1 2021. 117 funds tracked by Wall St. Rank hold KPTI as of Q4 2023.

  • J. Goldman & Co reported no remaining Karyopharm Therapeutics position as of Q4 2023 after selling out during the quarter.
  • J. Goldman & Co sold 8,000 Karyopharm Therapeutics shares in Q4 2023, an estimated $161K.
  • J. Goldman & Co first reported a position in Karyopharm Therapeutics in Q3 2019 and held it in 12 quarters.
  • J. Goldman & Co's Karyopharm Therapeutics position peaked at $14M in Q1 2021.
  • 117 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2023.

Based on J. Goldman & Co's 13F filing for Q4 2023, filed 14 Feb 2024.